Sold as 8-Mop, Oxsoralen, Oxsoralen-Ultra, Uvadex. Every FDA application for this active ingredient: 3 branded and 3 generic.
As of Nov 14, 2026, FDA lists 6 applications for Methoxsalen (sold as 8-Mop, Oxsoralen, Oxsoralen-Ultra and others), first approved Dec 3, 1954, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Methoxsalen | Part D | $592K | +9% | 100 |
| A New ECP Protocol for the Treatment of cGVHDChronic Graft Versus Host Disease · Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not applicable | Not yet recruiting | Nov 5, 2026 |
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposureColitis, Hepatitis · Therakos LLC | Phase 2 | Not yet recruiting | Jun 2, 2026 |
| Photopheresis in Early-stage Mycosis FungoidesCutaneous T Cell Lymphoma, Mycosis Fungoides · Columbia University | Phase 2 | Recruiting | Jan 11, 2023 |
| MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal PhotochemotherapyCutaneous T-Cell Lymphoma, Graft Vs Host Disease · Centre Hospitalier Universitaire de Besancon | Not applicable | Recruiting | Apr 19, 2022 |
| Extracorporeal Photopheresis in Sezary SyndromeSezary Syndrome · Oleg E. Akilov, MD, PhD | — | Recruiting | Dec 15, 2021 |
| Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic Sclerosis · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 | Recruiting | Aug 3, 2021 |
| Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.Kidney Transplantation · University Hospital, Angers | Not applicable | Recruiting | May 3, 2021 |
| X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and MelanomaAdvanced Solid Tumor Cancer · Immunolight, LLC | Phase 1 | Recruiting | May 15, 2020 |
| Dec 3, 1954 | 8-Mop, OxsoralenNDA 9048 · New molecular entity | Valeant Pharm Intl | 19 | Discontinued |
| Oct 30, 1986 | Oxsoralen-UltraNDA 19600 · New dosage form | Bausch | 12 | Marketed |
| Feb 25, 1999 | UvadexNDA 20969 · New dosage form | Therakos Development | 4 | Marketed |
| Jun 5, 2014 | MethoxsalenANDA 202687 | Onesource | 1 | Marketed |
| Jun 9, 2015 | MethoxsalenANDA 202603 | Actavis Inc | 0 | Discontinued |
| — | MethoxsalenANDA 87781 | Ani Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
